April 1, 1987Journal of Biological ChemistryOpen Access

Caldesmon inhibits skeletal actomyosin subfragment-1 ATPase activity and the binding of myosin subfragment-1 to actin.

Q: What is the clinical evidence from this study?

Intervention: Caldesmon. Primary outcome: Rate of hydrolysis of ATP by skeletal muscle myosin subfragment-1 and binding to actin.

View Full Paper

Ask AI

Bookmark

Key result

Caldesmon inhibits ATP hydrolysis by skeletal muscle myosin subfragment-1 by up to 95% and weakens its binding to actin.

Authors

JCJoseph M. ChalovichEast Carolina University PCPeter CorneliusHarvard University CBC.E. BensonEast Carolina University

Discussion

Member takes

Implication

Extends thin-filament regulation models in skeletal muscle; leaves open cardiac relevance and in vivo validation.

PICO

Intervention / Comparator

Caldesmon

Primary Outcome

Rate of hydrolysis of ATP by skeletal muscle myosin subfragment-1 and binding to actin

Cite This Study

Chalovich et al. (1987) studied this question. Caldesmon was evaluated on Rate of hydrolysis of ATP by skeletal muscle myosin subfragment-1 and binding to actin. Caldesmon inhibits ATP hydrolysis by skeletal muscle myosin subfragment-1 by up to 95% and weakens its binding to actin.

synapsesocial.com/papers/6a22fdd8c650520b07cb1fb9 https://doi.org/10.1016/s0021-9258(18)45633-5

View Full Paper

Ask AI

Bookmark

Caldesmon inhibits skeletal actomyosin subfragment-1 ATPase activity and the binding of myosin subfragment-1 to actin.

Discussion

Member takes

Implication

PICO

Cite This Study

Caldesmon inhibits skeletal actomyosin subfragment-1 ATPase activity and the binding of myosin subfragment-1 to actin.

Discussion

Member takes

Implication

PICO

Cite This Study

Also Consider

Also Consider